In the following years, increased release of ED-A+ Fn to serum/plasma was shown to be associated with rheumatoid vasculitis/arthritis, diabetes, preeclampsia, urinary bladder cancer, renal cell carcinoma, gastrointestinal and head and neck cancer, and parenchymal hematoma after thrombolytic therapy in acute ischemic stroke [44–52]. Here, EDA is linked to preeclampsia.